Country: Noregur
Tungumál: norska
Heimild: Statens legemiddelverk
Strontium (89Sr) klorid
GE Healthcare B.V.
V10BX01
Strontium (89Sr) chloride
150 MBq
Injeksjonsvæske, oppløsning
Hetteglass i blyemballasje 4 ml
C
Markedsført
2006-07-14
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metastron 37 MBq/ml solution for injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Strontium-89 chloride, 37 MBq/ml Strontium-89 is a pure beta emitter with an energy of 1.492MeV and a half-life of 50.5 days. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Solution for injection. Clear, colourless solution. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Metastron is indicated for the palliation of pain from bone metastases 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology ADULTS Metastron is an aqueous solution for intravenous injection and should be used without dilution. The recommended dose is 150MBq (4mCi) per injection. Alternatively in particularly heavy or light framed patients a dose of 2MBq (55 Ci)/kg 'fat-free' body weight may be used. This dosage is suitable for the elderly. Repeat administrations should not be performed within 3 months of the previous Metastron injection. Further administrations are not indicated in patients who have not responded to a previous administration of Metastron. ELDERLY POPULATION No dose adjustment is recommended based on age. RENAL IMPAIRMENT Careful consideration of the activity to be administered is required since an increased radiation exposure is possible in these patients. PAEDIATRIC POPULATION The product is not for administration to children. Method of administration Metastron is for single use only. (For repeat use after several weeks see section 4.4) The instructions for preparation of radiopharmaceuticals are given in section 12. For patient preparation, see section 4.4. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance or any of the excipients listed in section 6.1. Metastron should not be used as a primary treatment for cord compression secondary to spinal metastases where more rapid treatment may be necessary. Use of the product in patients with evidence of seriously compromised bone marrow, particularly low neutrophil and platelet counts, is not Lestu allt skjalið